Short answer
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $311M (up 126.8% year over year) with net income of −$94M.
Q1 2026 key financials · XBRL
- Revenue
- $311M
- +126.8% YoY
- Net income
- −$94M
- −28.9% YoY
- Operating margin
- -29.8%
- EPS (diluted)
- −$3.25
- +2.1% YoY
Source: XBRL data from the MADRIGAL PHARMACEUTICALS, INC. (MDGL) Q1 2026 10-Q on SEC EDGAR. USD.
MADRIGAL PHARMACEUTICALS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $311.3M, up 127% YoY from $137.3M, driven by increased U.S. Rezdiffra demand
- Net loss $94.4M vs $73.2M YoY, with operating loss $92.7M vs $79.3M
- Cost of sales $26.8M, up 495% YoY, primarily higher Roche royalties on Rezdiffra sales
- Cash, restricted cash and marketable securities $817.9M vs $988.6M at December 31, 2025
- Near-term cash usage expected to increase for development, commercialization, geographic expansion and business development; resources sufficient beyond one year
Risk Factors
- No Risk Factors section provided; supplied text begins with Item 2
- New insider-trading disclosure: David Soergel adopted a 10b5-1 plan for 4,293 shares
- Updated trading-plan exposure: Richard Levy modified a plan covering 5,682 shares
- New commercial-agreement exhibit: January 29, 2026 Roche amendment with certain portions omitted under Regulation S-K
- New lease amendment: March 14, 2026 agreement with KPG FF Owner, L.P.
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MADRIGAL PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.